Indication
Pathologic Myopia
1 clinical trial
2 products
Clinical trial
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic MyopiaStatus: Recruiting, Estimated PCD: 2026-02-02
Product
FaricimabProduct
Ranibizumab